Q1 2027 Shilpa Medicare Ltd Earnings Call Transcript
Key Points
- Record quarterly revenue of Rs. 469 crores, up 43% YoY, with EBITDA up 42% to Rs. 139 crores, marking the fourth consecutive quarter of record performance.
- Significant financial transformation: net debt-to-EBITDA improved from 6.7x to 1.3x, ROCE increased to 12.5% (18.3% adjusted for early-stage businesses), and credit rating upgraded to AA-.
- Strong growth across all segments: API revenue up 15% YoY, formulation revenue more than doubled (up 112% ex-licensing), and biologics revenue up 42% YoY.
- Robust pipeline with multiple near-term catalysts: 3 NCE programs for commercialization in FY28, 15 oncology product validations in FY27, and several complex formulations (e.g., Abraxane, Enzalutamide, Rotigotine patch) on track for FY28 launches.
- Biologics division advancing well: Aflibercept biosimilar on track for India launch in FY27, Nivolumab partnered with Orion for Europe, and multiple CDMO programs progressing, including one entering human trials in FY27.
- Strategic investments in novel entities (e.g., recombinant human albumin, ADC biosimilar) are on track to enter human studies in FY27, positioning the company for long-term growth.
- Strong operating leverage and margin expansion: gross margin at 71% and EBITDA margin at 30%, with management confident of sustaining similar levels.
- Company certified as a 'Great Place to Work', reflecting a positive organizational culture.
- Management indicates that significant capital investments are largely behind, with capacity utilization headroom in biologics and formulations to drive future growth without major new CapEx.
- CDMO business gaining traction with over 20 customers and 25+ NCE programs, including three late-stage programs expected to commercialize in FY28.
- Gross margin slightly declined due to rising raw material prices from global political situation, with only partial ability to pass on costs to customers.
- Regulatory risks remain a key challenge; unexpected issues with authorities could slow down growth trajectory.
- The OLC (Unicisive Therapeutics) program faced a CRL from USFDA, with refiling expected in Q3, creating uncertainty in that partnership.
- Management declined to provide specific product-level or segment-level financial details, limiting transparency for investors.
- Biologics segment still at early stage with low capacity utilization, and its contribution to overall revenue remains small (Rs. 52 crores), though growth potential is high.
- Europe revenue saw a decline (from Rs. 77 crores to Rs. 57 crores) due to tender-based supply variations, which could be volatile.
- Potential US tariffs on Indian pharmaceutical exports pose a risk, though management believes their complex product portfolio mitigates impact.
- The company's strategy of taking stakes in partner companies (e.g., MapTree, Alveolus Bio) involves higher risk and is not fully disclosed, adding uncertainty.
- Tax rate is expected to normalize at ~25% in coming quarters, which could impact reported PAT growth compared to the current quarter's negative tax rate benefit.
- Management refrained from providing forward guidance on revenue, margins, or ROCE, making it difficult for investors to model future performance.
Ladies and gentlemen, good day and welcome to Shilpa Medicare Limited's Q1 FY27 earnings conference call. (Operator Instructions)
I now hand the conference over to Mr. Monish Shah from Shilpa Medicare. Thank you and over to you Mr. Mohnish.
Thank you Virat and very warm welcome to everyone on our first quarter FY27 results call. Today from the management we have with us Mr. Keshav Guttada, Executive Director and CEO of Shilpa Pharma Life Science and Mr. Alpesh Lalala, CFO.
The financial results and the presentations are uploaded on the stock exchange and the transcript along with the audio will be available on our website and also on the stock exchanges. Please note today's discussion might include certain forward-looking statements based on current expectations and assumptions. These statements are subject to risks and uncertainties that could cause actual results to differ materially. The company undertakes no obligation to publicly update or revise any forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
